Studies have shown that PFKFB3 acts as a glycolytic activator to promote the growth of hepatocellular carcinoma and induce tumor angiogenesis (Dou et al., 2023), whereas inhibition of PFKFB3 prevents glycolycolytic mediated HCC proliferation  (Matsumoto et al., 2021). Here, PFKFB3 is linked to neoplasm.